New Posts
  • Hi there guest! Welcome to Register for free to join our community?

Potential COVId-19 drug therapies


Vaccines and projects not beyond the grant approval stage not included.

Kaletra (U.S.) ... originally developed for HIV/AIDS. Combination of lopinavir, which inhibits viral breakdown of proteins, and ritonavir, which inhibits production of enzymes that break down lopinavir, allowing it to be administered in safer doses. Lopinavir also shows experimental evidence of effectiveness against HPV while ritonavir is used against Hepatitis C. Weak evidence of effectiveness against other coronaviruses, performed poorly in U.S. clinical trials but used in conjunction with other drugs in China, S. Korea, N. Korea, Japan, Cuba, and Venezuela. Ritonavir in conjunction with another medication is in clinical trials in Switzerland.

Ampligen (U.S.): originally developed and used based on weak evidence of effectiveness in Argentina for chronic fatigue syndrome. Stimulates immune system recognition of pathogens. Petitioning China to allow clinical trials.

APN01 (Austria): developed for Coronavirus. Stimulates body to lower blood pressure and repair lung damage. Clinical trials in China.

Ganovo (U.S.): originally developed for Hepatitis C. Disrupts viral breakdown of proteins. Used in conjunction with other drugs in China and S. Korea

Heferon (Cuba): developed for hepatitis, also used for cancer. Stimulates cellular immune response. Used in Cuba, China, Japan, S. Korea, N. Korea, Venezuela, Russia, France, UK, and Germany.

ASC-09 (China): originally developed for HIV/AIDS. Disrupts viral breakdown of proteins. Clinical trials in China.

Tamiflu (U.S.): originally developed for influenza. keeps virus particles from escaping infected cells. Clinical trials in China.

Resochin (U.S.): quinine derivative. Originally developed for malaria. Also used for arthritis. Mechanism of action in this case is inhibiting virus from infecting cells and also possibly preventing viral reproduction in infected cells. Used in China and S. Korea. Clinical trials in U.S.

IFX-1 (China): developed for Coronavirus. Targets and kills Coronavirus particles. In clinical trials for Coronavirus and various skin disorders in China.

BCX4430 (U.S.): developed for influenza. prevents viral reproduction. Also used for many other viral infections. In use in S. Korea.

BXT-25 (U.S.): developed for suffocation. Gets oxygen to cells when the flow of blood is cut off. Experimental stage.

CYNK-001 (U.S.): developed for Coronaviruses, though not this one. Targets and kills infected cells before viruses can reproduce. Clinical trials in U.S., seeking clinical trials in China.

Tocilizumab (China): developed for Coronavirus. Regulates immune activity to make the immune system more effective. Clinical trials in China.

Leronlimab (U.S.): developed for Coronavirus. Also used for cancer and HIV. Targets and kills viruses. Clinical trials in U.S. and China.

Avifan (Japan): developed for Ebola. Also used for influenza. Prevents viruses from synthesizing proteins. Clinical trials in China.

Remdesivir (U.S.): developed for Ebola. Also used for Marburg, MERS, SARS, and other hemorrhagic and respiratory viruses. Prevents viruses from synthesizing proteins. Used in S. Korea, clinical trials in U.S., China, and Japan.

Camrelizumab (China): developed for cancer (carcinoma, also used for other cancers). Prevents immune system from relaxation response. Seeking clinical trials in China.

Thymosin (U.S.): developed for complications for skin punctures. Primarily used for hair loss, and illicitly as sports doping agent. Stimulates reproduction of healthy cells. Seeking clinical trials in China.

Brilacidin (U.S.): developed for cancers of the head and neck. Disrupts the protein shells of viruses. Experimental phase.

Prezcovix (U.S.): developed for HIV. Combination of darunavir, which prevents viral replication, and cobicistat, which inhibits production of enzymes by the liver, allowing more darunavir to enter the bloodstream and allowing higher doses of darunavir to be administered. Clinical trials in China.

Arbidol (Russia): developed for influenza. Prevents viruses from infecting cells. Clinical trials in Russia and China.

REGN3048(U.S.): developed for Coronavirus. Hunts down and kills Coronavirus. Experimental stage.

REGN3051 (U.S.): developed for Coronavirus. Hunts down and kills Coronavirus cells. Experimental stage.
Last edited:


Anybody but Trump!

Simon Fraser University

Simon Fraser University

11.2K subscribers


A team of researchers at SFU has received funding from CIHR to develop coronavirus testing kits using their pioneering imaging technology called Mango.


Anybody but Trump!
I have been hearing about this one... hoping it will pan out even if it is only temporary or a short term treatment.

FDA is working on treatment for coronavirus with blood from recovered patients
Experts say the potential treatment, which is already being tested in China, could be ready sooner than traditional drugs.
Dr. Arturo Casadevall was working from home in Baltimore on Thursday when his phone started to buzz with messages from colleagues. The commissioner of the Food and Drug Administration had just announced during a White House press briefing that the agency was investigating the possibility of using blood plasma donated by recovered coronavirus patients as a promising short-term treatment for the virus.
he method — essentially harvesting virus-fighting antibodies from the blood of previously infected patients — dates back more than a century, but has not been used widely in the United States in decades. The treatment was associated with milder symptoms and shorter hospital stays for some patients during the 2002 SARS outbreak, and initial reports from China suggest convalescent plasma might also be effective in dulling the effects of COVID-19, the disease caused by the new coronavirus, though Hahn cautioned that more testing was needed.

Patients tend to make large numbers of antibodies against an infecting pathogen, and these antibodies often circulate in the blood of survivors for months or years afterward. By collecting and transfusing a survivor’s serum or plasma — the liquid portion of blood left once cells and platelets have been removed — doctors could potentially boost an ailing patient's immune response, Casadevall said.